|Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial|
CN Sternberg, ID Davis, J Mardiak, C Szczylik, J Wagstaff, P Salman, ...
AMER SOC CLINICAL ONCOLOGY, 2010
|Enzalutamide in metastatic prostate cancer before chemotherapy|
TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
New England Journal of Medicine 371 (5), 424-433, 2014
|Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans|
ID Davis, W Chen, H Jackson, P Parente, M Shackleton, W Hopkins, ...
Proceedings of the National Academy of Sciences 101 (29), 10697-10702, 2004
|A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update|
CN Sternberg, RE Hawkins, J Wagstaff, P Salman, J Mardiak, CH Barrios, ...
European journal of cancer 49 (6), 1287-1296, 2013
|Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma|
TE Hutson, ID Davis, JPH Machiels, PL De Souza, S Rottey, B Hong, ...
Journal of Clinical Oncology 28 (3), 475-480, 2009
|Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015|
S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ...
Annals of Oncology 26 (8), 1589-1604, 2015
|Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017|
S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ...
European urology 73 (2), 178-211, 2018
|Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery|
M Schnurr, Q Chen, A Shin, W Chen, T Toy, C Jenderek, S Green, ...
Blood 105 (6), 2465-2472, 2005
|Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial|
RJ Motzer, C Porta, NJ Vogelzang, CN Sternberg, C Szczylik, J Zolnierek, ...
The lancet oncology 15 (3), 286-296, 2014
|Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma|
S RAMDAVE, GW THOMAS, SU Berlangieri, DM Bolton, IAN DAVIS, ...
The Journal of urology 166 (3), 825-830, 2001
|The Regulatory T Cell–Associated Transcription Factor FoxP3 Is Expressed by Tumor Cells|
LM Ebert, BS Tan, J Browning, S Svobodova, SE Russell, N Kirkpatrick, ...
Cancer research 68 (8), 3001-3009, 2008
|Tumor antigen expression in melanoma varies according to antigen and stage|
C Barrow, J Browning, D MacGregor, ID Davis, S Sturrock, AA Jungbluth, ...
Clinical Cancer Research 12 (3), 764-771, 2006
|Breast and prostate cancer: more similar than different|
GP Risbridger, ID Davis, SN Birrell, WD Tilley
Nature Reviews Cancer 10 (3), 205, 2010
|Rational approaches to human cancer immunotherapy|
ID Davis, M Jefford, P Parente, J Cebon
Journal of leukocyte biology 73 (1), 3-29, 2003
|Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells|
M Schnurr, T Toy, A Shin, G Hartmann, S Rothenfusser, J Soellner, ...
Blood 103 (4), 1391-1397, 2004
|A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC)|
CN Sternberg, C Szczylik, E Lee, PV Salman, J Mardiak, ID Davis, ...
Journal of Clinical Oncology 27 (15S), 5021-5021, 2009
|An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma|
ID Davis, BK Skrumsager, J Cebon, T Nicholaou, JW Barlow, NPH Moller, ...
Clinical Cancer Research 13 (12), 3630-3636, 2007
|Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli|
M Jefford, M Schnurr, T Toy, KA Masterman, A Shin, T Beecroft, TY Tai, ...
Blood 102 (5), 1753-1763, 2003
|Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial|
ID Davis, B Brady, RF Kefford, M Millward, J Cebon, BK Skrumsager, ...
Clinical Cancer Research 15 (6), 2123-2129, 2009
|ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling|
M Schnurr, T Toy, P Stoitzner, P Cameron, A Shin, T Beecroft, ID Davis, ...
Blood 102 (2), 613-620, 2003